Atrial septal defect (ASD) is a congenital heart defect in which blood flows between the atria of the heart chamber. Normally, the artria are separated by a dividing wall, the interatrial septum. If this septum is defective or absent then oxygen rich blood can flow directly from the left side of the heart to mix with the blood deficient in oxygen in the right side of the heart.
Atrial septal defect is one of the most common congenital cardiac diseases and usually affects women more than the men. It is characterized by a hole or defect in the interatrial septum that separates the heart’s two chambers (upper).
The opening in the septum usually closes when the baby is born; but in few cases if the opening does not close, the hole is referred to as atrial septal defect. Huge and long term atrial septal defects may lead to serious heart and lung damage.
This can lead to lower than normal oxygen levels in the arterial blood that supplies the brain, organs, and tissues. The ASD may not produce noticeable signs especially if the defect is small. During development of the fetus, the interatrial septum develops to separate the left and right atria.
The hole in the septum is called as a foremen ovale or foremen septum. It allows blood from the right atrium to enter the left atrium during fetal development. This opening allows blood to bypass the nonfunctional fetal lungs while the fetus obtains its oxygen from placenta.
Increasing disposable income of the Asian population would boost or increase the growth of arterial septal defect market in the years to come. Atrial Septal Defect Market size By Symptoms: Difficulty in breathing (dyspnea), frequent respiratory infections, swelling of legs and feet, Heart palpitations, Fatigue.
Atrial Septal Defect Market size By Diagnosis:
Electrocardiogram (ECG): ECG records the electrical activity of an individual and indentifies heart problems. Chest X-ray: with the help of chest X-ray, condition of the heart and lungs are detected. Cardiac Catherization: In this diagnosis test, a catheter is inserted into the heart via vein and any congenital heart defects can be diagnosed including amount of oxygen in the blood. Transesophageal echocardiography (TEE): The test provides an ultrasound image to provide a clear image of the atria.
Pulse oximetrey: This test helps to detect whether oxygenated blood is mixing with deoxygenated blood, thereby confirming any type of heart defect. The medications which are used to reduce the signs and symptoms of aerial septal defect include beta blockers, anticoagulants and anti-platelet agents. In some instances, surgery is also done to repair an atrial septal defect such as open-heart surgery and cardiac cauterization.
Atrial Septal Defect Market size By Geographical Region: North America, Europe, Asia Pacific, and Rest of the World (RoW).
North America holds the largest market size followed by Europe. The prime factors driving the growth of artial septal defect market size in these regions are high prevalence of genetic disorders and growing awareness in the population concerning arterial septal defects.
The technology advancement in the treatment of congenital heart diseases is also accentuating the growth of the market. The size of the market will be increased during the forecast period of 2014-2025.
The Asia Pacific is the most profitable market for the growth of atrial septal defect. The factor that would propel the growth of the market in Asia Pacific is presence of large population base and emerging economies such as China, Malaysia, India, and Vietnam.
The Key Players include Asklepion Pharmaceuticals, LLC, Actelion Ltd, Novo Nordisk A/S, Abbott Laboratories, INO Therapeutics, LLC and others.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.